靶向肽受体放射性核素治疗^177Lu-DOTATATE改变关节炎症
本文讨论生长抑素受体高表达为肽受体放射性核素治疗提供基础,放射性核素可用于炎症检测与治疗选择。作者报告一例靶向肽受体放射性核素治疗后炎症性关节病显著缓解。
要点
- 分化良好的神经内分泌肿瘤高表达生长抑素受体,为靶向肽受体放射性核素治疗提供基础。
- 放射性核素不仅可检测、表征和分期炎症,还可用于个体化治疗选择。
- 作者病例中靶向肽受体放射性核素治疗使炎症性关节病显著缓解。
核心结论
- 靶向肽受体放射性核素治疗在本例中使炎症性关节病显著缓解。
- 放射性核素可用于炎症的体内检测、表征、分期及个体化治疗选择,同一概念可扩展至感染治疗。
研究设计与样本
- 本文为病例报告,描述一例接受靶向肽受体放射性核素治疗^177Lu-DOTATATE的炎症性关节病患者。
主要发现
- 靶向肽受体放射性核素治疗在本例中使炎症性关节病显著缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High and frequent expression of somatostatin receptors in differentiated neuroendocrine neoplasms has paved the way for receptor-based, targeted peptide receptor radionuclide therapy especially for nonoperable or metastatic disease. Besides tumors, radiation, in one form or another, has been tested to treat inflammatory disease as well, and this goes back to the early 1990s when the first case of pneumonia treated with radiation showed complete resolution. Currently, radiotracers help in not only in vivo inflammation detection, characterization, and staging but also, and more importantly, for selection of treatment in individual patients. The same concept could be applied to treatment of infection, by coupling the radioisotopes to ligands that target sterile or nonsterile inflammation. In our case, targeted peptide receptor radionuclide therapy showed remarkable resolution of inflammatory joint disease.
引用
- Usmani S, Rasheed R, Ahmed N, et al. Targeted Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE Alters Joints Inflammation. Clin Nucl Med. 2024. PMID: 39716406. doi:10.1097/RLU.0000000000005553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。